Business
Notice of Interim Results
Notice of Interim Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n \n \n 1 September 2022\n \n \n \n \n \n \n Futura Medical plc\n \n \n \n \n (\"Futura\" or the \"Company\")\n \n \n \n \n Notice of Interim Results\n \n \n \n \n \n \n \n \n \n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, will announce its interim results for the six months ended 30 June 2022 on Tuesday, 13th September 2022.\n \n \n \n \n \n James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website.\n \n \n \n -ENDS-\n \n \n \n For further information please contact:\n \n \n \n Futura Medical plc\n \n \n \n James Barder, Chief Executive\n \n \n Angela Hildreth, Finance Director and COO\n \n \n Email:\n \n \n [email protected]\n \n \n \n \n Tel: +44 (0) 1483 685 670\n \n \n \n \n www.futuramedical.com\n \n \n \n \n Nominated Adviser and Sole Broker:\n \n \n \n Liberum\n \n \n \n Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings\n \n \n Tel: +44 (0) 20 3100 2000\n \n \n \n \n \n For media enquiries please contact:\n \n \n \n \n \n \n \n \n Optimum Strategic Communications\n \n \n \n Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt\n \n \n Email:\n [email protected]\n \n \n Tel: +44 (0)20 3922 0890\n \n \n \n \n \n \n About Futura Medical plc\n \n \n \n Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys®technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value cre...